Weight-loss drug manufacturer Novo Nordisk cuts 9000 jobs — and its profit forecast
Short excerpt below. Click through to read at the original source.
New CEO Mike Doustdar is kitchen-sinking the costs of restructuring the company to focus on diabetes and anti-obesity drugs.